rapamycin


Also found in: Medical, Wikipedia.

rap·a·my·cin

 (răp′ə-mī′sĭn)
n.

[From Rapa (Nui) (Easter Island), where the soil sample containing the actinomycete producing sirolimus was obtained + -mycin.]
Mentioned in ?
References in periodicals archive ?
The team treated the cells with rapamycin, an mTOR inhibitor that is already used clinically in TSC to reduce the size of TSC-related tumors and prevent TSC-related seizures.
resTORbios lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.
The company plans to use the proceeds to advance the development of RTB101, a selective Target of Rapamycin Complex 1 inhibitor, through Phase 2b clinical trial and, if successful, into a Phase three clinical program, as an immunotherapy to decrease the incidence of respiratory tract infections in elderly patients.
When the protein was combined with rapamycin -- a drug used to coat heart stents and prevent organ transplant rejection -- its effectiveness was further improved, the researchers found.
Background: Triggering receptor expressed on myeloid cell-1 (TREM-1) may play a vital role in mammalian target of rapamycin (mTOR) modulation of CD8[sup]+ T-cell differentiation through the transcription factors T-box expressed in T-cells and eomesodermin during the immune response to invasive pulmonary aspergillosis (IPA).
I don't know if, 5 years from now, we'll all be taking low-dose rapamycin as an antiaging drug, but we might, especially if someone figures out the ideal dose," he said at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Research Foundation.
ITP showed rapamycin increased median and maximum lifespan in both male and female mice.
A compound called rapamycin may actually be able to postpone aging and death, according to the (https://www.
Mammalian target of rapamycin (mTOR) is a central regulator of cell growth and metabolism and sufficient to induce specific metabolic processes, including de novo lipid biosynthesis (Duvel et al.
The final cell suspensions were divided into four major groups: Control group, HMGB1 group (HMGB1 was added to pancreatic acinar cells at a final concentration of 1 [micro]g/mL), AG490 group (the JAK2 inhibitor AG490 was added to the cultured cells 30 minutes before HMGB1 induction at a final concentration of 25 pmol/L), and the rapamycin group (the STAT3 inhibitor rapamycin was added at a final concentration of 40 ng/ml 30 minutes before the HMGB1 induction).
Rapamycin, which is an inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway, has a variety of cellular functions and is known to possess both immunosuppressant and anti-tumor properties.
Sirolimus, an inhibitor of the mammalian target of rapamycin (mTQR), is used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders.